TABLE 1.
Demographic and clinical characteristics of probable DLB males and females.
| Clinical cohort (N = 327) | Research‐oriented cohort (N = 165) | |||||||
|---|---|---|---|---|---|---|---|---|
| Males | Females | n, M/F | t stat/χ2 (P) | Males | Females | n, M/F | t stat/χ2 (P) | |
| Age, mean (SD) | 72.07 (8.21) | 74.81 (8.13) | 204/123 | 2.940 (0.004) | 68.73 (8.40) | 70.02 (9.03) | 119/46 | 0.867 (0.387) |
| Years of education, mean (SD,range) | 10.91 (4.00, 2 to 22) | 10.04 (3.75, 3 to 18) | 170/102 | 1.771 (0.078) | 13.71 (4.63, 5 to 22) | 13.41 (3.20, 6 to 22) | 119/46 | 0.446 (0.656) |
| Disease duration (years), mean (SD) | 3.23 (2.01) | 3.26 (2.58) | 90/27 | 0.070 (0.944) | 5.83 (4.63) | 5.02 (3.20) | 97/26 | 0.839 (0.403) |
| MMSE, mean (SD) | 22.58 (3.93) | 21.90 (4.33) | 201/121 | 1.451 (0.148) | 22.33 (5.47) | 24.44 (4.18) | 119/45 | 2.350 (0.020) |
| Visual hallucinations (presence) | 55.2% | 64.4% | 174/101 | 2.221 (0.136) | 53.4% | 58.7% | 116/46 | 0.366 (0.545) |
| Cognitive fluctuations (presence) | 82.7% | 87.5% | 110/80 | 0.816 (0.366) | 83.9% | 82.2% | 112/45 | 0.068 (0.795) |
| Parkinsonism (presence) | 75.3% | 80.7% | 166/88 | 0.945 (0.331) | 90.6% | 78.3% | 117/46 | 4.478 (0.034) |
| Probable RBD (presence) | 78% | 50.0% | 41/14 | 0.085 (0.052) | 80.2% | 71.8% | 111/39 | 1.183 (0.277) |
| Fazekas scale, n 0/1/2/3 | 10/70/30/35 | 7/38/28/20 | 145/93 | 6530.0 (0.662) | 4/25/10/5 | 1/6/4/1 | 44/12 | 249.5 (0.748) |
| WMH volume (cm3), mean (SD) | N/A | 16.01 (13.65) | 16.39 (12.26) | 119/46 | 0.166 (0.868) | |||
| TIV (mm3), mean (SD) | N/A | 1632.00 (134.99) | 1441.99 (117.27) | 119/46 | 8.397 (<0.001) | |||
| AD co‐pathology (presence) | 14.0% | 15.4% | 43/13 | 1.000 (0.603) | 10.6% | 10.8% | 85/37 | 1.000 (0.598) |
| APOE ε4 carriers (presence) | 67.5% | 46.2% | 40/13 | 0.200 (0.147) | 45.2% | 38.6% | 115/44 | 0.561 (0.454) |
Note: Statistically significant differences are shown in bold (P ≤ 0.05).
Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E;F, female; M, male; MMSE, Mini‐Mental State Examination; N/A, not applicable; RBD, rapid eye movement sleep behavior disorder; TIV, total intracranial volume; WMH, white matter hyperintensities.